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Abstract
Background: In 2017, measles elimination was verified in Bhutan, and the country appears to 
have sufficiently high vaccination coverage to achieve rubella elimination. However, a measles and 
rubella serosurvey was conducted to find if any hidden immunity gaps existed that could threaten 
Bhutan’s elimination status.
Methods: A nationwide, three-stage, cluster seroprevalence survey was conducted among 
individuals aged 1–4, 5–17, and >20 years in 2017. Demographic information and children’s 
vaccination history were collected, and a blood specimen was drawn. Serum was tested for 
measles and rubella immunoglobulin G (IgG). Frequencies, weighted proportions, and prevalence 
ratios for measles and rubella seropositivity were calculated by demographic and vaccination 
history, taking into account the study design.
Results: Of the 1325 individuals tested, 1045 (81%, 95% CI 78%–85%) were measles IgG 
seropositive, and 1290 (97%, 95% CI 95%–99%) were rubella IgG seropositive. Rubella IgG 
seropositivity was high in all three age strata, but only 47% of those aged 5–17 years were measles 
IgG seropositive. Additionally, only 41% of those aged 5–17 years who had documented receipt of 
two doses of measles– or measles-rubella–containing vaccine were seropositive for measles IgG, 
but almost all these children were rubella IgG seropositive.
Conclusions: An unexpected measles immunity gap was identified among children 5–17 years 
of age. It is unclear why this immunity gap exists; however, it could have led to a large outbreak 
and threatened sustaining of measles elimination in Bhutan. Based on this finding, a mass 
vaccination campaign was conducted to close the immunity gap.
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1. Introduction
The Global Vaccine Action Plan calls for elimination of measles and rubella in five World 
Health Organization (WHO) Regions by 2020 [1]. The elimination of measles and rubella is 
defined as the absence of endemic cases of measles or rubella for at least 12 months in the 
presence of a high-quality surveillance system [2]. In 2017, the Kingdom of Bhutan, a 
country with a population of approximately 800,000, was verified as having eliminated 
measles; and in 2018, it was verified as having controlled rubella (an intermediary step 
toward rubella elimination) [3,4]. Bhutan has achieved this success because of a strong 
immunization program that provides free vaccinations. In 1979, 1-dose measles vaccination 
was introduced into the routine immunization schedule for those 9 months of age. In 2006, 
rubella vaccination was introduced into the routine immunization schedule in combination 
with measles vaccine, and a 2-dose measles rubella (MR) vaccine schedule was established 
for children aged 9 and 24 months. To help close immunity gaps, nationwide measles 
campaigns were conducted in 1995 and 2000, and a nationwide measles-rubella campaign 
was conducted in 2006. Coverage with the first and second doses of MR vaccine (MR1 and 
MR2, respectively) has been high since 2011; and the country’s efforts have resulted in a 
dramatic decrease in measles and rubella cases, with recent measles cases attributed to 
importation from other countries (Fig. 1).
High administrative vaccination coverage estimates might be misleading, however, in 
assessing the number of susceptible persons in the population. Administrative coverage 
estimates might be inaccurate because of incorrect numerators (e.g., counting doses given to 
older-aged children outside the target age group) as well as denominators (i.e., the target 
population) [5]. The development of immunity after vaccination involves many factors, 
including the person’s age at vaccination, underlying genetics/immune system, and vaccine 
failure due to storage/handling conditions [6,7]. Serosurveys can identify susceptibles in a 
population and provide an estimate of population immunity; for measles and rubella, 
serosurveys reflect exposure either to vaccination or disease [8].
Bhutan is surrounded by India and China, countries that are endemic for measles and 
rubella, and thus it is at high risk for importations of virus. Bhutan has experienced measles 
outbreaks caused by importation in recent years, despite high vaccination coverage. 
However, these outbreaks were small, and it was unclear if there were significant immunity 
gaps in the population, thus making it challenging to target vaccination efforts to prevent 
future outbreaks [9]. The Bhutan Ministry of Health, in collaboration with the World Health 
Organization conducted a measles-rubella serosurvey (combined with a hepatitis B and 
hepatitis C serosurvey) to identify any remaining immunity gaps that needed to be addressed 
to sustain measles elimination and to achieve rubella elimination.
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2. Methods
In April 2017, a nationwide, cross-sectional, 3-stage cluster survey was conducted to 
estimate the prevalence of measles and rubella immunoglobulin G (IgG) antibodies and 
biomarkers for hepatitis B and C infections among persons residing in Bhutan. This report 
provides the measles and rubella seroprevalence results; findings from the hepatitis 
serosurvey are reported elsewhere (under review). Three age strata were targeted based on 
the history of the hepatitis B vaccination program and risk for chronic hepatitis B 
acquisition: 1–4 years of age (birth years 2012–2016, referred to as younger children); 5–17 
years of age (birth years 2000–2012, referred to as older children); and >20 years (born 
before 1997, referred to as adults). Those born from 1997 to 1999 were excluded because 
they were born during the start of the hepatitis B vaccination program, and hepatitis B 
serosurvey data from these cohorts would have been difficult to interpret, given variable 
implementation of hepatitis B vaccination and consequent low coverage. It was assumed that 
their measles and rubella seroprevalence would not differ significantly from those of a 
similar age who were included in the survey.
2.1. Sample size
For younger children, the sample size was calculated based on the estimated measles IgG 
seroprevalence; a minimum effective sample size of 123 was calculated assuming 95% 
seroprevalence, a one-side confidence interval of −5%, and α = 0.05. Accounting for the 
cluster design, a target of 8 young children per primary sampling unit, an intraclass 
correlation = 0.1, and a 15% nonresponse rate, the sample size was increased to 245 young 
children. Among the older children and adults, the sample size was calculated based on the 
expected prevalence of chronic hepatitis B infection, because this calculation would result in 
a larger sample size than the size needed for the MR serosurvey (245 persons in each age 
group), based on an expected 95% seroprevalence of measles and rubella in each group. In 
brief, a sample size of 657 was calculated for older children, assuming 1% seroprevalence of 
chronic hepatitis B, precision of ±1%, a design effect of 1.5, and α = 0.05, with a 13% non-
response rate. For adults, a sample size of 785 was calculated assuming a chronic hepatitis B 
prevalence of 5%, precision of ±2%, a design effect of 1.5, and α = 0.05, with a 13% non-
response rate. To achieve the targeted sample sizes, it was estimated that 30 clusters of 29 
households (870 households in total) would have to be sampled, based on the 2005 census, 
to enroll the minimum sample of younger children.
2.2. Sampling
Based on a 2005 national census, 30 enumeration areas were selected by probability 
proportional to estimated size with replacement for the first stage of sampling. For the 
second stage, 29 households were randomly selected from an updated list of households. For 
the third stage, all eligible persons in the selected household, defined as those in one of the 
three age strata and living in the household for at least 6 months, were enumerated. One 
person per age stratum per household was randomly selected using a smartphone 
application. If the selected individual was absent, the household was revisited up to three 
times on two different days. If the selected person remained absent, the person was marked 
as absent and not replaced.
Wangchuk et al. Page 3
Vaccine. Author manuscript; available in PMC 2020 October 08.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
2.3. Data collection
Consent was requested from adults and from parents or caregivers of children before 
participation in the serosurvey; assent was also requested from those 10–17 years of age. A 
specific questionnaire was developed for each age group. If the person consented, the age-
appropriate questionnaire was administered by trained field workers. The questionnaire 
included demographic and background data and, for younger and older children, measles 
and rubella vaccination history. If documented vaccination history was not available for 
younger children, vaccination history was obtained based on recall; for older children, only 
documented vaccination history was collected. The documented vaccination history 
reflected vaccine doses administered via routine immunization services, not via 
supplemental immunization activeities (SIAs).
2.4. Specimen collection and laboratory testing
Approximately 10 ml of blood were collected by venipuncture from older children and 
adults and approximately 5 ml of blood from younger children. Serum was separated in the 
field, transported at 2° to 8 °C to the Royal Centre for Disease Control, and subsequently 
stored at −20 °C until testing. All samples were tested using Siemens Enzygnost® Anti-
measles Virus/IgG and Anti-rubella Virus/IgG ELISA kits (Siemens, Healthcare Diagnostics 
Products, GmbH Marburg, Germany). Test results were interpreted according to 
manufacturer’s instructions, with titers of <150 mIU/ml considered negative for measles and 
<4 mIU/ml considered negative for rubella. A random sample of 10% of specimens was sent 
to the WHO South-East Asia Regional Reference Laboratory for Measles and Rubella at the 
National Institute of Health (NIH) in Bangkok, Thailand, for quality assurance. Less than 
10% of samples tested at the NIH Thailand were discordant with results obtained in Bhutan, 
so no additional retesting was done.
2.5. Additional testing
Based on unexpected findings of low IgG seroprevalence, a subset of serum specimens were 
sent to the US Centers for Disease Control and Prevention for plaque reduction 
neutralization test (PRNT), regarded as the gold standard for measuring measles immunity 
because it measures functional neutralizing antibody, which is considered a correlate of 
protection [10]. Titers of <120 mIU/ml were considered true negatives.
2.6. Data management/analysis
The data were double-entered into an Epi-Info7 database (Atlanta, GA). Data were analyzed 
with STATA® SE 14.1 (College Station, TX, USA) and SAS v9.4 (Cary, NC, USA). Measles 
and rubella vaccination rates were calculated by age group. All specimens with measles or 
rubella IgG titers above the aforementioned ELISA cutoffs were considered seropositive. 
PRNT results are presented for the subset of specimens tested by PRNT, but findings were 
not used to define seropositive and seronegative for the study. Frequencies, weighted 
proportions, and 95% logit confidence intervals (CI) using the Taylor series method were 
calculated for measles IgG and rubella IgG positivity by age group, sex, education level, and 
vaccination status. Weights were applied, factoring in the survey design, sampling 
probabilities, nonresponse rate, and the population distribution of Bhutan. Prevalence ratios 
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were calculated to identify factors related to measles and rubella seropositivity. χ2 p-values 
were calculated for all remaining analyses. When evaluating the discordance between 
measles and rubella seropositivity, the differences in the percentage discordant (% measles 
negative among rubella positive minus % rubella negative among measles positive) and 
corresponding 95% CI were calculated. A 95% CI in the difference that did not include zero 
was considered statistically significant. For descriptive analyses conducted among small 
subgroup populations, unweighted proportions are presented.
2.7. Human Subjects’ Rights and Ethics
The researchers obtained informed consent from participants or caregivers before testing. 
The study protocol was approved by the Research and Ethical Board of Health, Bhutan, and 
the WHO Research Ethics Review Committee. This activity was reviewed in accordance 
with CDC human research protections procedures and was determined to be human subject 
research, but CDC involvement did not constitute direct engagement in human subject 
research.
3. Results
The serosurvey was conducted during March–April 2017. Of 870 preselected households, 
781 (90%) agreed to participate in the survey, 18 (2%) refused to participate, and 71 (8%) 
were ineligible (non-residential, abandoned, or no adults available) (Fig. 2). From these 781 
households, 2866 age-eligible persons were identified, and 1372 age-eligible persons were 
selected. Fourteen (1%) refused, 33 (2%) responded to the questionnaire but did not have 
blood drawn, and 1325 (97%) were enrolled, interviewed, and had their blood tested. 
Serosurvey participants (n = 1325) and non-participants (n = 33) were similar with respect to 
country of birth, education/maternal education, and vaccination history (among children) 
(Table 1). However, more children were nonparticipants than adults.
3.1. Vaccination
Among 550 participating children, 396 (64%) submitted information on measles and rubella 
vaccination provided via routine immunization services. Vaccination data were available by 
vaccination card for 226 (54%) older children and for 155 (85%) younger children. An 
additional 15 (13%) younger children had vaccination data provided by recall. Among 173 
younger children, 123 (72%) had received at least two doses of measles- and rubella-
containing-vaccine (MRCV). Among 243 5- to 11-year-olds, 128 (47%, 95% CI 38% to 
57%) had received at least two doses of MRCV; among 132 12- to 17-year-olds, 3 (1%, 95% 
CI 0% to 3%) had received at least two doses of measles vaccine.
3.2. Seroprevalence
Of 1325 persons tested, 1045 (81%, 95% CI 78% to 85%) were measles IgG positive and 
1290 (97%, 95% CI 95% to 99%) were rubella IgG positive (Table 2). Rubella IgG 
seroprevalence was >95% in all three age strata. However, measles IgG seroprevalence 
varied by stratum; 150 (85%, 95% CI 77% to 91%) of 173 young children were measles IgG 
seropositive compared with 179 (47%, 95% CI 39% to 56%) of 377 older children and 716 
(92%, 95% CI 89% to 95%) of 775 adults. To evaluate if there was a difference within the 
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5–17-year-old stratum, additional analysis was performed. Among 243 children 5–11 years 
of age, 120 (52%, 95% CI 42% to 62%) were measles IgG seropositive; among 132 children 
12–17 years of age, 59 (42%, 95% CI 31% to 54%) were measles seropositive. Neither 
measles nor rubella IgG seropositivity varied significantly by sex or education status. When 
measles IgG seropositivity was evaluated by vaccination status, those who had had two 
doses of measles vaccine or MRCV were significantly more likely to be measles IgG 
seropositive than those who had received no doses [prevalence ratio 2.8 (95% CI 1.03–
7.77)], but vaccination status was not associated with higher rubella IgG seropositivity 
(Table 2).
Among the 1325 participants, 1028 (80%, 95% CI 76% to 84%) were both measles and 
rubella IgG seropositive (Table 3). The 5- to 17-year-old stratum had the smallest proportion 
(47%) who were both measles and rubella seropositive (Table 3). This finding was similar 
when the data were further analyzed by 5- to 11-year-old and 12- to 17-year-old subgroups 
(data not shown). Similarly, children aged 5–17 years had the highest discordance in measles 
and rubella IgG seropositivity, 49% (95% CI 40% to 57%), compared with 15% (95% CI 
8% to 22%) among 1- to 4-year-olds and 5% (95% CI 2% to 8%) among adults.
3.3. Vaccination status and seroprevalence by age group
When measles IgG seropositivity was evaluated by age group and number of vaccination 
doses received, 110 (88%) of 123 1- to 4-year-olds who received two doses of MRCV were 
IgG seropositive, compared with 70 (58%) of 128 5- to 11-year-olds (p < 0.0001). All three 
12- to 17-year-old children who received two doses of measles vaccine were IgG 
seropositive (Table 4). Given this large difference, vaccination details were reviewed. There 
was no clustering of documented two-dose measles or MRCV recipients who were measles 
IgG seronegative by geographic location, year of birth, or year of first or second dose 
vaccine receipt. Among the 73 children aged 5–17 years who received two measles or 
MRCV dose and were measles IgG seronegative, 68 (93%) received the first dose at or after 
9 months of age, and 64 (88%) received the second dose at or after 24 months of age. 
Vaccination timing was similar among children who were seropositive and seronegative.
Given the unexpectedly low seropositivity among 2-dose vaccine recipients, 58 measles IgG 
seronegative samples by ELISA testing from 5- to 11-year-olds who had documented receipt 
of two doses of MRCV vaccine were further tested for measles IgG by PRNT at US-CDC. 
Fifty-seven (98%) of the 58 samples were rubella IgG positive by ELISA testing at the 
Royal Centre for Disease Control. In contrast, 46 of 58 (79%, the negative predictive value) 
were <120 mIU/ml for measles IgG by PRNT and thus true measles negatives. Six (10%) 
had IgG titers from 120 to 150 mIU/ml, below the detectable limit of ELISA used in this 
serosurvey; these were classified as seronegative by ELISA but were true positives. Six 
(10%) had titers > 150 mIU/ml by PRNT; these were true positives, erroneously classified as 
seronegative by ELISA.
4. Discussion
Measles elimination has been verified in Bhutan and the country is on track to eliminate 
rubella, but immunity to measles in this study was only 81%, which is below the critical 
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threshold of 95% recommended to achieve and maintain elimination [11]. This unexpected 
immunity gap to measles, confirmed by PRNT in a subset of children, was identified 
primarily among children aged 5–17 years and could have resulted in a large outbreak and 
re-establishment of measles endemicity. In contrast, rubella immunity was high among the 
three age strata studied and is sufficient for achieving rubella elimination.
The cause of the low measles IgG seroprevalence among children aged 5–17 years is 
unknown. Children aged 5–11 years were eligible to receive two doses of MRCV in the 
routine immunization schedule. Almost all those aged 12–17 years (birth year 2000–2005) 
were eligible for one dose of monovalent measles vaccine, but they were also eligible for at 
least one additional dose of measles-rubella vaccine given during the 2006 nationwide SIA; 
those born between June 2005-December 2005 were only eligible for one dose of 
monovalent measles vaccine. The routine immunization data evaluated in this study showed 
that very few 12 to 17-year-olds received a second dose of measles vaccine. Despite these 
differences in opportunities for vaccination, there was no statistical difference in measles 
IgG seroprevalence between those aged 5–11 years and those 12–17 years of age. There was 
no clear-cut relationship identified between receipt of measles or rubella vaccine and 
seropositivity, but this relationship is challenging to evaluate because natural and vaccine-
derived immunity are indistinguishable by testing. Additionally, data were only collected for 
doses in the routine immunization schedule and not for doses provided by SIAs because the 
latter were not documented.
It is also unclear why many 5- to 17-year-olds were measles IgG seronegative but rubella 
IgG seropositive. One potential hypothesis is that some 5- to 17-year-old children were 
naturally infected with rubella virus but never exposed to natural measles virus infection nor 
were vaccinated. This hypothesis, however, does not explain the low measles IgG 
seropositivity among 2-dose vaccine recipients. Another hypothesis is that those 5- to 17-
year-old children with documented vaccination were immunized against rubella but were not 
immunized against measles; one study has shown that the measles component of the vaccine 
is much more sensitive to excursions outside of cold chain as compared with the rubella 
component [12]. However, this hypothesis seems unlikely because this would have to have 
been ongoing for 12 years (2000–2012). Another hypothesis is that immunity to measles 
vaccination has waned over time, whereas rubella immunity has not. Globally, there is little 
evidence that this is a significant problem because most measles cases are among 
unimmunized individuals or those too young to vaccinate [13]. However, some countries 
have experienced what appears to be waning immunity to measles vaccination [14-18]; the 
reason for waning immunity is unclear and potentially could be caused by mishandling of 
vaccine at the time of administration, resulting in the administration of a less potent dose.
This study has a few notable limitations. First, this is a nationally representative survey, and 
subnational variations could exist that could not be identified here. This study excluded 
those aged 18–20 years because of the objectives of the concomitant hepatitis B serosurvey; 
it is unclear if they have a measles immunity gap similar to that among 5- to 17-year-olds or 
those >20 years of age. Measles and rubella IgG testing is not 100% correlated with 
immunity. PRNT was done on a subset of 2-dose documented vaccine recipients who were 
IgG negative, and most of the PRNT results substantiate that those who were IgG negative 
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were not immune; thus, this limitation is unlikely to significantly impact the results. 
Vaccination data were collected by card where available, but by recall among those 1–4 
years of age, when a card was not available, which is subject to recall bias [19], although 
only a small (13%) proportion of children aged 1–4 years provided vaccination information 
by recall. However, vaccination history was unknown for 28% of children. Finally, although 
there was a high participation rate, the target sample size was not reached because it is hard 
to predict how many individuals per household would be eligible a priori.
Bhutan was fortunate that the measles immunity gap identified in this survey had not yet 
resulted in a large outbreak. Based on the measles immunity gap identified in this survey, 
two rounds of a nationwide measles-rubella SIA were conducted during 2017–2018, with 
the goal of achieving 95% measles immunity in the population to prevent an impending 
measles outbreak. In the first round, persons aged 9 months to 40 years were targeted in 
high-risk areas based on the measles epidemiology; in the second round, those aged 6–24 
years were targeted nationwide. Continued high-coverage with two doses of MRCV for all 
eligible children will be needed to maintain measles and rubella elimination.
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Fig. 1. 
Measles and rubella cases and measles and measles-rubella vaccination coverage — Bhutan, 
1981–2017 [20].
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Fig. 2. 
Participation and enrollment in the measles and rubella serosurvey — Bhutan, 2017.
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